Thromboembolism Archives - Page 3 of 4

Vascular endothelial growth factor receptor tyrosine-kinase inhibitors do not appear to be associated with an increased risk of venous thrombotic events in patients with advanced cancers.

ASH 2012

ASH: First Int’l Good Clinical Practice Guidelines for Use of Antithrombotics

By

Traci Dantoni

December 8, 2012

Global experts called on colleagues attending the 54th American Society of Hematology Annual Meeting and Exposition to help disseminate and implement the first International Good Clinical Practice Guidelines for the use of antithrombotics.

General Oncology

Cisplatin Significantly Increases Risk of VTEs in Patients with Advanced Solid Tumors

By

Debra Hughes, MS

November 13, 2012

Patients with advanced solid tumors treated with cisplatin have a significant increased risk of venous thromboembolism compared with non-cisplatin-based chemotherapy.

Gynecologic Cancer

ESA Increases VTE Risk but Does Not Affect OS in Women Administered Bevacizumab for Ovarian Cancer

By

Bryant Furlow

September 21, 2012

Erythropoietin stimulating agents and granulocyte colony stimulating factor do not affect OS among patients with ovarian cancer who receive bevacizumab plus chemotherapy, but ESA is associated with a significantly-elevated risk of venous thrombotic events.